Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy
Copyright © 2014 Elsevier B.V. All rights reserved..
A LC-MSMS method for the simultaneous determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots samples was developed and validated. The method employs an ultrasound-assisted liquid extraction and a reversed phase separation in an Acquity(®) C18 column (150×2.1 mm, 1.7 µm). Mobile phase was a mixture of formic acid 0.1% (v/v) pH 2.7 and acetonitrile (gradient from 60:40 to 50:50, v/v). Total analytical run time was 8 min. Precision assays showed CV % lower than 10.75% and accuracy in the range 94.5 to 110.3%. Mean analytes recoveries from DBS ranged from 40% to 92%. The method was successfully applied to 91 paired clinical DBS and plasma samples. Dried blood spots concentrations were highly correlated to plasma, with rs>0.83 (P<0.01). Median estimated plasma concentrations after hematocrit and partition factor adjustment were: TAM 123.3 ng mL(-1); NDT 267.9 ng mL(-1), EDF 10.0 ng mL(-1) and HTF 1.3 ng mL(-1,) representing in average 98 to 104% of the actually measured concentrations. The DBS method was able to identify 96% of patients with plasma EDF concentrations below the clinical threshold related to better prognosis (5.9 ng mL(-1)). The procedure has adequate analytical performance and can be an efficient tool to optimize adjuvant breast cancer treatment, especially in resource limited settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Talanta - 132(2015) vom: 05. Jan., Seite 775-84 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Antunes, Marina Venzon [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.08.2015 Date Revised 09.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.talanta.2014.10.040 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM24429688X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24429688X | ||
| 003 | DE-627 | ||
| 005 | 20231224134411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.talanta.2014.10.040 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0814.xml |
| 035 | |a (DE-627)NLM24429688X | ||
| 035 | |a (NLM)25476377 | ||
| 035 | |a (PII)S0039-9140(14)00868-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Antunes, Marina Venzon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.08.2015 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2014 Elsevier B.V. All rights reserved. | ||
| 520 | |a A LC-MSMS method for the simultaneous determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots samples was developed and validated. The method employs an ultrasound-assisted liquid extraction and a reversed phase separation in an Acquity(®) C18 column (150×2.1 mm, 1.7 µm). Mobile phase was a mixture of formic acid 0.1% (v/v) pH 2.7 and acetonitrile (gradient from 60:40 to 50:50, v/v). Total analytical run time was 8 min. Precision assays showed CV % lower than 10.75% and accuracy in the range 94.5 to 110.3%. Mean analytes recoveries from DBS ranged from 40% to 92%. The method was successfully applied to 91 paired clinical DBS and plasma samples. Dried blood spots concentrations were highly correlated to plasma, with rs>0.83 (P<0.01). Median estimated plasma concentrations after hematocrit and partition factor adjustment were: TAM 123.3 ng mL(-1); NDT 267.9 ng mL(-1), EDF 10.0 ng mL(-1) and HTF 1.3 ng mL(-1,) representing in average 98 to 104% of the actually measured concentrations. The DBS method was able to identify 96% of patients with plasma EDF concentrations below the clinical threshold related to better prognosis (5.9 ng mL(-1)). The procedure has adequate analytical performance and can be an efficient tool to optimize adjuvant breast cancer treatment, especially in resource limited settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 4-Hydroxytamoxifen | |
| 650 | 4 | |a Dried blood spot | |
| 650 | 4 | |a Endoxifen | |
| 650 | 4 | |a LC–MS/MS | |
| 650 | 4 | |a N-desmethyltamoxifen | |
| 650 | 4 | |a Tamoxifen | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Tamoxifen |2 NLM | |
| 650 | 7 | |a 094ZI81Y45 |2 NLM | |
| 650 | 7 | |a afimoxifene |2 NLM | |
| 650 | 7 | |a 17197F0KYM |2 NLM | |
| 650 | 7 | |a 4-hydroxy-N-desmethyltamoxifen |2 NLM | |
| 650 | 7 | |a 46AF8680RC |2 NLM | |
| 650 | 7 | |a N-desmethyltamoxifen |2 NLM | |
| 650 | 7 | |a OOJ759O35C |2 NLM | |
| 700 | 1 | |a Raymundo, Suziane |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Staudt, Dilana Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Gössling, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Peteffi, Giovana Piva |e verfasserin |4 aut | |
| 700 | 1 | |a Biazús, Jorge Villanova |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalheiro, José Antônio |e verfasserin |4 aut | |
| 700 | 1 | |a Tre-Hardy, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Capron, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Haufroid, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Wallemacq, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartsmann, Gilberto |e verfasserin |4 aut | |
| 700 | 1 | |a Linden, Rafael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Talanta |d 1966 |g 132(2015) vom: 05. Jan., Seite 775-84 |w (DE-627)NLM114409137 |x 1873-3573 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2015 |g day:05 |g month:01 |g pages:775-84 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.talanta.2014.10.040 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2015 |b 05 |c 01 |h 775-84 | ||